Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Neurology

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Lower serum uric acid level strongly predict short-term poor functional outcome in acute stroke with normoglycaemia: a cohort study in China

  • Shuolin Wu1, 2,
  • Yuesong Pan2, 3, 4, 5,
  • Ning Zhang1, 2,
  • Wang Yong Jun2, 3, 4, 5,
  • Chunxue Wang1, 2, 3, 4, 5Email author and
  • On Behalf of the Investigators for the Survey on Abnormal Glucose Regulation in Patients With Acute Stroke Across China (ACROSS-China)
BMC NeurologyBMC series – open, inclusive and trusted201717:21

https://doi.org/10.1186/s12883-017-0793-6

Received: 10 June 2016

Accepted: 9 January 2017

Published: 1 February 2017

Abstract

Background

Conflicting results on the correlation between hyperuricemia and the prognosis of stroke had been reported and the close association between serum uric acid (SUA) and abnormal glycomatabolism might further complicate the assessment of the correlation. We aimed to investigate SUA in predicting the prognosis of acute stroke in different glycometabolism status.

Methods

A total of 2907 patients aged from 18 to 85 (1220 diabetes mellitus (DM), 777 prediabetes and 910 normoglycemia) were selected from the Abnormal Glucose Regulation in Patients with Acute Stroke across China (ACROSS-China) study. The patients were divided into groups according to the SUA quartile as well as decile. The correlations between SUA and the poor outcome (mRS > 2) at discharge were assessed stratified by glucose metabolism status. Multivariate logistic regression was used to analyze the potential risk factors of poor in-hospital outcome of stroke and the risk-adjustment of the correlation between SUA and the prognosis of stroke. P < 0.05 was considered statistically significant.

Results

SUA were divided first as Quartile1 to 4 (Quartile1 < 221 μmol L−1; Quartile2 (221–286) μmol L−1; Quartile3 (286–352) μmol L−1 and Quartile4 > 352 μmol L−1), then as decile1 to 10. In normoglycaemia, SUA quartiles, deciles and continuous SUA concentration were independently significantly associated with poor outcome. Q1 was independently associated with the higher possibility of poor functional outcome (compared to Q4, odds ratios (ORs) with 95% confidential interval (CI) was 3.79 (1.23–8.67) in Q1); Lower level of SUA in DM was also associated with poor functional outcome at discharge compared to the highest level of SUA(Q4)(OR with 95% CI, 2.07 (1.05–4.08)), however, lower SUA level was also related to severer stroke at admission in DM as well as in prediabetes (P < 0.001 in DM and 0.023 in prediabetes) and severer stroke resulted in worse functional outcome at discharge (OR with 95% CI, 12.15 (8.08–18.21) in DM and 11.58 (7.50–23.25) in prediabetes). But in normoglycamic stroke, SUA levels did not differ in stroke severity at admission (P = 0.066).

Conclusions

Low SUA level (<221 μmol L−1) independently and strongly predicts the short-term poor functional outcome in acute stroke with normoglycaemia other than diabetes or prediabetes.

Keywords

Uric acidDiabetes mellitusStrokeRisk factors

Background

The association between hyperuricemia and cardiovascular disease has been well documented for a very long time. However, conflicting results on the correlation between hyperuricemia and the incidence and prognosis of stroke had been reported. In a meta-analysis study, Kim, et al. reported that hyperuricemia increased the risk of both the ischemic stroke and the hemorrhagic stroke as well as the risk of post-stroke mortality [1]. Several other groups also found that the post-stroke hyperuricemia could significantly exacerbate the outcome of stroke [24]. Other study suggested that the effect of pre-stroke hyperuricemia on poor post-stroke outcome, especially in diabetic patients, was still questionable [5]. Holme and his group also suggested that hyperuricemia might be rather a complementary indicator than an independent risk factor of AS [6]. Kramer et al. found that the importance of the pre- cardiovascular disease hyperuricemia in predicting cardiovascular disease mortality was only significant in the pre-diabetic and type 2 diabetic patients but not in the normoglycemic patients [7]. Some investigators even found that post-stroke hyperuricemia might have played a protective role in the prognosis of stroke [812]. Miedema et al. found no evidence to support the association between the SUA level and the outcome of stroke in their study [13].

Hyperuricemia, hyperglycaemia and cardiovascular disease are found to be co-morbid disease [14]. Hyperuricaemia is also positively associated with prediabetes diagnosed according to impaired fasting glucose criteria other than subjects with normal fasting glucose [15]. A meta-analysis also ascertain that hyperglycaemia is contributed to the development of diabetes and impaired fasting glucose [16]. Even in normal range of SUA, uric acid is related to diabetes onset in healthy lean women [17]. Since the close and complicated association between SUA and prediabetes as stated above and diabetes was a well-known risk factor of stroke [18], it is in very need to assess and compare the effect of SUA on stroke prognosis stratified by different glycometabolism status. Newman et al. reported that a combination of the post-stroke hyperuricemia and diabetes could significantly increase the risk of adverse events, including recurrent stroke, cardiovascular events even death, in post-stroke patients [3]. In another study, Zhang et al. found that the post-stroke hyperuricemia was associated with better short-term outcome of stroke in non-diabetes patients [12]. However they failed to distinguish between the pre-diabetes and the normoglycemia patients in their study. In our study, the association between SUA and the outcome of acute primary stroke would be assessed in both diabetes and normoglycemia patients. The pre-diabetes patients were excluded in our study.

Methods

Patient selection

ACROSS-CHINA” was a large prospective cohort study conducted in China from 2008 to 2009 that investigated on abnormal glucose regulation in acute first-ever stroke (within 14 days), in which a total of 3450 patients with ischemic stroke, intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH) were successively recruited from 34 hospitals across China [19, 20]. Acute stroke was diagnosed according to World Health Organization combined with CT or MRI confirmation [21].

All the patients without previous DM were required to perform a standard oral glucose tolerance test (OGTT) at the day 14 ± 3 after stroke onset or before discharge according to the World Health Organization criteria [22]. Patients were categorized as diabetes, pre-diabetes or normoglycemia according to their OGTT results. One hundred and forty-four patients without SUA values and 399 patients with missing OGTT results were excluded respectively. In the remaining 2,907 patients, there were 1220 diabetics, 777 prediabetics and 910 normoglycaemic patients (Fig. 1).
Fig. 1

Flow chart of patient selection. OGTT, oral glucose tolerance test

Data collection

Demographic, education degree, tobacco use and alcohol consumption, physical exam and a National Institute of Health Stroke Scale (NIHSS) score were obtained at admission. A detailed history of previous diseases, such as hypertension, coronary artery disease and atrial fibrillation, were also recorded. Body mass index (BMI) was defined as body weight (kg)/the square of height (m). Participants without a history of diabetes were required to take an OGTT test within 24 h after the hospital admission. The lab tests included blood routine test, high density lipoprotein, low density lipoprotein, creatinine, SUA, homocysteine, glucose and insulin level, et al. All the lab tests were performed within 24 h after admission at fasting condition by the certified central laboratory. SUA was measured by the urine enzyme endpoint method. The index of insulin resistance was calculated with the Homeostasis Model Assessment 2- Insulin Resistance (HOMA2-IR) method [23]. A Modified Rankin Scale (mRS) was calculated in every participant at discharge to evaluate the in-hospital outcome of stroke.

The criteria of diagnosing abnormal glycometabolism

The OGTT result and the blood glucose level were used to divide patients into three categorise based on the 1999 World Health Organization (WHO) criteria. The details were as follow: (1) Diabetes mellitus (DM) was defined as fasting plasma glucose (FPG) ≥ 7.0 m mol L−1 and/or 2-h value (2-h-value) ≥ 11.1 m mol L−1; (2) Pre-diabetes consisted of both impaired glucose tolerance (IGT) and impaired fasting glucose (IFG). IGT was defined as FPG < 7.0 m mol L−1 and a 2-h-value between 7.8 mmol/L and 11.1 m mol L−1. IFG was defined as fasting glucose value between 6.1 m mol L−1 and 7.0 m mol L−1 with a normal 2-h-value; (3) normoglycemia was defined as FPG < 6.1 m mol L−1 and a 2-h-value < 7.8 m mol L−1. Patients who had a history of DM or had ever received hyperglycemic agents for at least 6 months were also assigned to the DM group. All the prediabetics were newly-diagnosed.

Other variables definition

Tobacco use was categorized as ‘current’, ‘previous’ or ‘never’ smoking. ‘Current smoking’ was defined as that the individual was an active smoker at the time of the stroke. ‘Previous smoking’ was defined as that the individual had quit smoking 1 year prior to the stroke. ‘Never smoking’ was defined as that the individual had never smoked prior to the stroke. Alcohol consumption was categorized as ‘never drinking’, ‘mild drinking’,‘moderate to severe drinking’. ‘Moderate or severe drinking’ was defined as that the individual consistently consumed ≥2 standard size alcoholic beverages per day. ‘Mild drinking’ was defined as that the individual consumed <2 standard size alcoholic beverages per day. ‘Never drinking’ was defined as that the individual had never consumed any alcoholic beverages. Stroke severity was categorized by the NIHSS score as mild stroke (NIHSS < 9) or severe stroke (NIHSS ≥ 9) [4].

Outcome assessment

The primary endpoint comprised death and dependency with mRS >2 [24, 25]. Death (mRS = 6) was recorded within 14 ± 3 days after admission to the hospital. Dependency (mRS = 3 to 5) was assessed at 14 ± 3 days after the index date of hospital admission or at hospital discharge. Death indicated all-cause death according to the International Classification of Diseases, 10th Revision. Neurological improvement and deterioration were used as supplemental indicators to describe the association between SUA and stroke outcome. Neurological improvement was defined as 4 point decrease in NIHSS during hospitalization or a 0 point status on NIHSS at discharge. Neurological deterioration was defined as 1 point increase in NIHSS during hospitalization [24, 26, 27].

Statistical analysis

Baseline clinical features were compared stratified by different diabetes diagnosis and functional outcome. All continuous variables were presented as mean ± standard deviation for normal distribution and median (Quartile 1 to 3) for skewed distribution. Kolmogorov-Smirnov test was used for normal distribution test. Categorical variables were presented as frequencies and/or prevalence/incidence rate. For the continuous variables, when the group numbers were more than two, if the variable was normal distribution, one-way ANOVA test was used to perform the comparison (LSD-test for variables with homogeneity of variance and Games-Howell test for variables with heterogeneity of variance), otherwise Kruskal-Wallis H test was performed instead; when the group numbers were just two, if the variable was normal distribution, T-test was used to perform the comparison, otherwise Mann–Whitney U test was used instead. For categorical variables, the comparisons were used Chi-square test and Fisher exact test. The adjustment of the correlation between different variables was done by multivariate logistic regression. Variables with a P value < 0.1 in univariate analysis were included in the multivariate regression test. Variables, which had shown potential association to the outcome of stroke during the literature search, were also included in the multivariate regression test. The independent factors included in the multivariate analysis were age, gender, education degree, tobacco use, alcohol consumption, BMI, high density lipoprotein, low density lipoprotein, creatinine, systolic and diastolic blood pressure, HOMA2-IR, homocysteine, a history of coronary heart disease, a history of hypertension, a history of atrial fibrillation, stroke types and stroke severity at admission. The use of Aspirin, Diuretics and Coumadin [28], which could influence SUA concentration, were also analyzed. SUA was compared between “use” and “non-use” of them respectively and stratified by different glycometabolism first, then it will be recognized as a confounding factor if P < 0.05 and entered into the according multivariate analysis. The fitness of the models was evaluated by using the Hosmer and Lemeshow goodness-of-fit test and a P value > 0.2 was considered as a good fit. All the statistical analyses were done with SPSS ver. 19.0 software (SPSS Inc., Chicago, IL). A P <0.05 was considered statistically significant.

Results

Comparison of the characteristics of patients in different glucose metabolism groups

Patients with normoglycemia accounted for 31.3% of the study population. The differences in the characteristics of patients among different groups were shown in Table 1. The normoglycemia group had highest percentage of males (67.7% vs. 64.5%vs. 58.3%, P < 0.001) and higher prevalence of current smoking (P = 0.036). The mean level of age in this group was significantly younger than that of the DM or prediabetes group (P < 0.001). In the physical exam and the lab test, the patients in the normoglycemia group had significantly lower blood pressure, BMI, NIHSS score, low density lipoprotein level and HOMA2-IR than that in the DM or prediabetes group (all P < 0.05). The high density lipoprotein, homocysteine in the normoglycemia group were significantly higher than that in the DM or prediabetes group (all P < 0.05). Previous histories of coronary heart disease, hypertension or atrial fibrillation in thenormoglycaemia group were significantly less common than that in the DM group (all P <0.05). Ischemic stroke was the most common type of stroke in all groups, followed by intracerebral hemorrhage and SAH. The percentages of stroke types were significantly different in patients with different glycometabolism status (P <0.001).
Table 1

Baseline Clinic features according to glycometabolism diagnosis by OGTT

Clinic features

Diabetes mellitus (n = 1220)

Prediabetes (n = 777)

Normoglycemia (n = 910)

P

Age, y (median, Q1–3)

64 (55, 73)

61 (52,72)

58 (49, 69))

<0.001

Male, n (%)

711(58.3)

501 (64.5%)

616 (67.7)

<0.001

Tobacco use, n (%)

   

0.036

 Never

712 (58.4)

428 (55.1)

480 (52.7)

 

 Quit

110 (9.0)

74 (9.5)

79 (8.7)

 

 Current

351 (28.8)

246 (31.7)

320 (35.2)

 

Alcohol consumption, n (%)

   

0.164

 Mild

213 (17.5)

132 (17.0)

171 (18.8)

 

 Moderate to severe

165 (13.5)

131 (16.9)

152 (16.7)

 

 Never

817 (67.0)

494 (63.6)

564 (62.0)

 

BMI, kg/m2 (median, Q1–3)

25.0 (22.9,27.3)

24.5 (22.5,26.8)

24.2 (22.0,26.2)

<0.001

NIHSS (median,Q1-Q3)

5 (2–9)

5 (2,9)

4 (2–8)

0.002

Creatinine,m mol L−1 (median, Q1–3)

71.2 (58.0, 87.0)

72.0 (60.0, 87.0)

71.8 (59.9, 86.7)

0.425

LDL, m mol L−1 (median, Q1–3)

3.0 (2.4, 3.6)

2.9 (2.3, 3.5)

2.8 (2.3, 3.4)

0.001

HDL,m mol L−1(median, Q1–3)

1.1(1.0, 1.3)

1.2 (1.0, 1.4)

1.2 (1.1, 1.4)

<0.001

Systolic blood pressure, mmHg (median, Q1–3)

150 (138, 160)

143 (130, 160)

146 (130, 160)

<0.001

Homocysteine, μ mol L−1, (median, Q1–3)

14.4 (11.5, 18.7)

15.5 (12.0, 21.9)

15.7 (12.3, 22.8)

<0.001

HOMA2-IR (median, Q1–3)

2.5 (1.6, 4.0)

1.9 (1.1, 3.0)

1.6 (0.9, 2.5)

<0.001

Past medical history, yes, n (%)

    

 Coronary artery disease

172 (14.1)

87 (11.2)

90 (9.9)

0.009

 Hypertension

795 (65.2)

470 (60.5)

514 (56.5)

<0.001

 Atrial fibrillation

66 (5.4)

54 (6.9)

31 (3.4)

0.006

Stroke types, n (%)

   

<0.001

 IS

1015 (83.2)

541 (69.6)

675 (74.2)

 

 ICH

174 (14.3)

185 (23.8)

198 (21.8)

 

 SAH

31 (2.5)

51 (6.6)

37 (4.1)

 

OGTT the oral glucose tolerance test, BMI body mass index, LDL low density lipoprotein, HDL high density lipoprotein, NIHSS the National Institutes of Health Stroke Scale, HOMA2-IR the correctly solved computer model for homeostasis model assessment of insulin resistance, IS ischemic stroke, ICH intra-cerebral hemorrhage, SAH subarachnoid hemorrhage

Comparison of the characteristics of patients with different functional outcomes of the stroke

There were no significant differences between the favorable outcome group and the poor outcome group in the mean level of age, BMI, HOMA2-IR, low density lipoprotein level, high density lipoprotein level, the prevalence of the histories of coronary heart disease or hypertension. Compared to the favorable outcome group, the mean level of creatinine was significantly lower in the poor outcome group, whereas the blood pressure and homocysteine level were significantly higher in the poor outcome group. The percentage of moderate to severe alcohol consumption as well as the percentage of severe stroke and atrial fibrillation in the poor outcome group was significantly higher than that in favorable outcome group. The percentage of mild drinking was significantly higher in favorable outcome group than that in the poor outcome group. Ischemic stroke was the most common type of stroke in both groups. Cardioembolic ischemic stroke was only accounted for 5.7% (n = 91) of the total patients with poor functional outcome. The intracerebral hemorrhage was more commonly seen in the poor outcome group than that in the favorable outcome group while ischemic stroke and SAH were more prevalent in the favorable outcome group. DM was more prevalent in the poor outcome while normoglycemia were more commonly seen in the favorable outcome group (Table 2).
Table 2

Baseline Clinic features according to poor functional outcomes evaluated by mRS > 2

Clinic features

Favorable outcomes (n = 1305)

Poor functional outcomes (n = 1602)

P

Age, y

60 (52, 71)

62 (53, 72)

0.003

Male, n (%)

954 (73.1)

1089 (68.0)

<0.001

Tobacco use, n (%)

  

0.036

 Never

692 (53.0)

928 (57.9)

 

 Quit

126 (9.7)

137 (8.6)

 

 Current

436 (33.4)

481 (30.0)

 

Alcohol consumption, n (%)

  

0.006

 Never

811 (62.1)

1064 (66.4)

 

 Mild

266 (20.4)

250 (15.6)

 

 Moderate to severe

192 (14.7)

256 (16.0)

 

BMI(kg/m2)

24.6 (22.5,26.7)

24.5 (22.4,26.8)

0.637

NIHSS scales

  

<0.001

 <9

1256 (96.2)

996 (62.2)

 

 9–18

30 (2.3)

474 (29.6)

 

  > 18

7 (0.5)

124 (7.7)

 

Creatinine (m mol L−1)

72.7 (60.0, 87.5)

70.0 (57.5,85.0)

0.002

LDL(m mol L−1)

2.8 (2.3,3.5)

2.9 (2.3,3.5)

0.290

HDL(m mol L−1)

1.2 (1.0,1.4)

1.2 (1.0,1.4)

0.125

Systolic blood pressure (mmHg)

140 (130,160)

150 (134,161)

<0.001

Homocysteine (μmol L−1)

14.6 (11.4,19.8)

15.8 (12.3,21.4)

<0.001

HOMA2-IR

1.8 (1.1,3.0)

2.0 (1.2,3.1)

0.055

Past medical history, yes, n (%)

  

 Coronary heart disease

146 (11.2)

203 (12.7)

0.230

 Hypertension

785 (60.2)

994 (62.0)

0.296

 Atrial fibrillation

53 (4.1)

98 (6.1)

0.013

Stroke types, n (%)

  

<0.001

 Ischemic stroke

1059 (81.1)

1172 (73.2)

<0.001

 Cardioembolic

44 (3.4)

91 (5.7)

 

 Large-artery atherosclerosis

565 (43.3)

819 (51.1)

 

 Small-artery occlusion Lacunar

367 (28.1)

200 (12.5)

 

 Other demonstrated or undemonstrated

38 (2.9)

25 (1.6)

 

 ICH

176 (13.5)

381(23.8)

 

 SAH

70 (5.4)

49 (3.1)

 

Glycometabolism status

  

<0.001

 Diabetes mellitus

500 (38.3)

720 (44.9)

 

 Prediabetes

348 (26.7)

429 (26.8)

 

 Normoglycaemia

457 (35.0)

453 (28.3)

 

mRS modified Rankin scale, BMI body mass index, LDL low density lipoprotein, HDL high density lipoprotein, NIHSS the National Institutes of Health Stroke Scale, HOMA2-IR the correctly solved computer model for homeostasis model assessment of insulin resistance, IS ischemic stroke, ICH intra-cerebral hemorrhage, SAH subarachnoid hemorrhage

Analysis on medication use and SUA concentration

There are 1542 patients with data on aspirin, 20 patients on Coumadin and 124 patients on Diuretics. SUA levels were compared between “use” and “non-use” of them respectively and stratified by different glycometabolism. After that a significant association was found between Aspirin use and SUA level among normal glycemic stroke patients (Additional file 1: Table S3, Additional file 2: Table S4 and Additional file 3: Table S5). Aspirin use was then entered into the multivariate analysis on SUA and the outcome among normoglycaemic stroke patients.

Correlation between SUA and poor functional outcome at discharge

Univariate analysis of SUA quartiles on poor outcome

The patients were divided into quartile groups (Q1 to Q4) based on their SUA level. The concentrations of SUA in these groups were as follow: Q1 < 221 μmol L−1, Q2 221-286 μmol L−1, Q3 286-352 μmol L−1 and Q4 > 352 μmol L−1 (DM group, NQ1=307, NQ2 = 306, NQ3 = 310, NQ4 = 291; Prediabetes group, NQ1=184, NQ2 = 198, NQ3 = 190, NQ4 = 198; Normoglycaemia group, NQ1=229, NQ2 = 218, NQ3 = 211, NQ4 = 248). In both diabetic and normoglycemic strokes, the occurrence of stroke poor outcome decreased across the increasing SUA levels from Q1 to Q4(P = 0.019 in DM, 0.016 in normoglycemia), however, it didn’t differ in SUA quartiles in prediabeteic strokes (P = 0.110 in prediabetes) (Fig. 2).
Fig. 2

Poor outcome rates depending on serum uric acid quartiles stratified by glycometabolism status. OGTT, the oral glucose tolerance test. Q1-4 indicates serum uric acid levels by quartiles. Q1 to Q4 were Q1, <221 μmol L−1; Q2, (221–286) μmol L−1; Q3, (286–352) μmol L−1 and Q4, >352 μmol L−1

Multivariate analysis of SUA quartiles on poor functional outcome at discharge

To further evaluate the correlation between the SUA level and the poor post-stroke outcome, the SUA level along with other potential risk factors of poor post-stroke outcome were introduced into a regression model as independent variables and the multivariate logistic regression was used to assess the adjusted correlation between the SUA level and the outcome of stoke. The NIHSS score was entered into the regression model as an ordinal variable with the cut-off point of 9 first and then as a continuous one.

The final results of the regression showed that there was a negative correlation between the SUA level and the occurrence rate of poor outcome of stroke in normoglycemic group. In the normoglycemic group, the occurrence rate of poor outcome in Q1 group was also significantly higher than that in the Q4 group (OR = 3.79, 95% CI 1.23–8.67, P =0.020) (Fig. 3); In DM group, the possibility of poor outcome in lowest SUA group (Q1) was significantly higher than that in Q4 (OR = 2.07, 95% CI 1.05–4.08). The possibility of poor outcome in Q2 and Q3 groups were not significantly higher than that in Q4 (Q2: OR = 1.33, 95% CI 0.71–2.47; Q3: OR = 1.79, 95% CI 0.99–3.26). In prediabetes, the possibility of poor outcome did not differ in SUA quartiles (all P > 0.05). The Hosmer and Lemeshow goodness-of-fit test results (χ 2, P) were (8.839, 0.356), (110.982, 0.215) and (4.558, 0.755) in the DM, prediabetes and the normoglycemia group, respectively (Fig. 3).
Fig. 3

Association between uric acid quartiles and poor outcomes in multivariate logistic regression analysis a ( a adjusted for age, gender, stroke types, tobacco use, alcohol consumption, education level received, a history of hypertension, coronary artery disease or atrial fibrillation, NIHSS <9 VS ≥9, body mass index, homocysteine, systolic blood pressure, diastolic blood pressure, HOMA-IR, low density lipoprotein, high density lipoprotein, creatinine. In normoglycaemic subjects, Aspirin use was included as a binary variable in the analysis). NIHSS indicates the National Institutes of Health Stroke Scale; HOMA2-IR indicates the correctly solved computer model for homeostasis model assessment of insulin resistance

In normoglycaemic stroke patients, NIHSS was then entered as a continuous variable into multivariate analysis instead of NIHSS as a binary variable. The association was still significant after the new adjustment (Additional file 4: Table S7).

In normoglycaemic stroke patients, further analysis was performed stratified by sex (Additional file 5: Table S6). There was 620 male and 290 female in normoglycaemic group. In male, after adjusted for the same variables as the above, the lowest level of SUA is still an independent risk factor for the poor functional outcome (OR with 95% CI 5.06(1.17–12.05), P = 0.031). However it was not the case in female patients (OR with 95% CI 9.21(0.98–38.66), P = 0.158).

Multivariate analysis of SUA deciles on poor functional outcome

SUA was re-divided into decile groups (D1 to D10) in different glucose metabolism groups. The SUA quartile groups in previous regression model were replaced with SUA deciles and a new regression model was calculated. The ORs of the incidence rate of poor outcome obtained from the regression model were used in the curve-fitting analysis. The curve-fitting results showed a U-shape curve and the cubic curve had the highest R2 value in both the DM group and the normoglycemia group (Fig. 4a and c). The occurrence of poor outcome significantly decreased across SUA deciles from D1 to D9 in both normoglycemia and DM strokes (P for trend0.003 and 0.010, respectively), while it did not differ from D1-10 in prediabetes group (Fig. 4 b, P for trend, 0.568).
Fig. 4

Association between serum uric acid deciles and poor outcomes in multivariate logistic regression analysisa ( a adjusted for the same variables as those in Fig. 3). *indicates the reference OR (the OR of D10 = 1). Reference point not included as basis for fit of regression lines. D1-10 indicates 1st decile to the 10th decile of serum uric acid. D1 to D10 (μmol L−1) in ‘Diabetes’ were <169, 169–206, 206–235, 235–261, 261–286, 286–308, 308–334, 334–368, 368–424, >424. D1 to D10 (μmol L−1) in “Prediabetes” were <155, 155–208, 208–237, 237–266, 266–287, 287–314, 314–342, 342–380, 380–438, >438. D1-10 (μmol L−1) in ‘Normoglycaemia’ were <151, 151–201, 201–235, 235–260, 260–288, 288–316, 316–343, 343–381, 381–425, >425

Multivariate analysis of continuous SUA concentration on poor functional outcome

SUA were further reintroduced into the multivariate analysis as a continuous variable. After adjusting for the same confounding factors as the above, higher SUA was still significantly independently associated with the less possibility of poor outcome in patients with normoglycaemia, while the association did not exist in patients with DM or prediabetes (Table 3). The Hosmer and Lemeshow goodness-of-fit test results (χ 2, P) were (9.873, 0.274) in DM, (4.719, 0.787) in prediabetes and (5.621, 0.690) in normoglycemia group, respectively.
Table 3

Association between SUA as a continuous variable and poor outcome stratified by glycometabolism statusa

Glycometabolism status

Odds ratio with 95% confidence intervals

P

Diabetes mellitus

0.98 (0.97–1.00)

0.135

Prediabetes

1.00 (1.00–1.01)

0.105

Normoglycaemia

0.99 (0.98–1.00)

0.022

aadjusted for the same variables as those in Fig. 3

SUA concentration and Neurological functional change stratified by glycometabolism

SUA and Neurological improvement

In diabetic and prediabetic stroke patients, SUA quartiles were significantly associated with neurological improvement. Patients with the lowest level of SUA (<221umol/L) occupied 28.5% and 30.6% within the diabetes and prediabetes being neurological improved (both P <0.05. Additional file 6: Table S1. Additional file 7: Figure S1).

SUA and Neurological deterioration

There were no significant association between SUA and neurological deterioration in all the glycometabolism statuses (Additional file 8: Table S2. Additional file 9: Figure S2).

Correlation between SUA levels and stroke severity at admission

The correlation between stroke severity (NIHSS < 9, 9–18,>18) and the SUA level was also analyzed. The patients were divided into 3 groups according to NIHSS of <9, 9–18 and >18, respectively. The correlation between stroke severity and the SUA quartile was calculated (Fig. 5). In DM and prediabetes, the percentage of patients with low SUA (Q1) in the severe stroke group (NIHSS > 18) was significantly higher than that in the mild stroke group (NIHSS < 9) (P < 0.001for DM and 0.023 for prediabetes). There were no significant differences in the SUA level across different stroke severity in the normoglycemia group (P = 0.066).
Fig. 5

Association between serum uric acid levels and stroke severity stratified by glycometabolism status. SUA indicates serum uric acid. NIHSS indicates the National Institutes of Health Stroke Scale

Other variables associated with the poor functional outcome of the stroke in multivariate analysis

NIHSS ≥9 was a significant risk factor of the poor outcome in all patients (In diabetes, 12.15 (8.08–18.21); In prediabetes, 11.58 (7.50–23.25); In normoglycemia, 18.40 (7.90–25.45)). In normoglycemia group, higher BMI as well as higher systolic blood pressure were also related to significantly higher risk of poor outcome (BMI 1.09 (1.02–1.18), systolic blood pressure 1.02 (1.01–1.18)).

Discussion

Most of previous studies suggested that hyperuricemia was a risk factor of stroke. In the present study, SUA values in predicting poor functional outcomes after stroke differed in 3 glycometabolism statuses. Lower SUA level (SUA < 220 μmol L−1) was an independent risk predictor of the short-term prognosis of the acute first-ever stroke in patients with normoglycemia other than DM or prediabetes and such an effect might has gender difference. In the present study, the relationship is much more robust in male than in female normoglycaemic stroke patients.

Difference in the association of SUA level and post-stroke poor functional outcome among different glycometabolism status

The correlation between the SUA level and the poor post-stroke outcome in the normoglycemia patients was different from that in the DM or prediabetes patients in our study. Low SUA level was an independent predictor of the poor outcome of stroke in the normoglycemia patients but not in DM or prediabetes group. In DM group, a paradox association was found: 1) the association between the lowest SUA quartile (Q1) and the poor outcome was observed as significant (Fig. 3. P = 0.032) but the trend from Q1-Q4 was not (Fig. 3. P for trend = 0.109); 2) the association between SUA deciles and poor outcome was in a significant trend (Fig. 4 a. P for trend 0.003); 3) however, the significant association disappeared when assessment was performed between the continuous SUA concentration and the poor outcome (Table 3 . P = 0.135). In prediabetes group, possibility of poor outcome in the lower SUA levels was similar to that in the higher SUA levels either SUA was introduced into the multivariate analysis as a categorical variable or a continuous variable.

These debated results might be attributed to the negative association between SUA levels and stroke severity in DM and prediabetes (Fig. 5 a and b. P < 0.001 for DM and 0.023 for prediabetes). The percentage of the lower SUA level was significantly increased across the aggravated stroke severity in diabetes and prediabetes group, and stroke severity (measured as NIHSS level) was also significantly associated with the poor outcome in the multivariate analysis, we speculated that the effect of the low SUA level in DM on the poor outcome of stroke might be carried out via its correlation with the severity of stroke. On the contrary, based on the fact that there was no correlation between the SUA level and the severity of stroke in normoglycemia patients (Fig. 5c. P = 0.066), the association of SUA and poor outcome was independent of stroke severity at baseline in normoglycemia patients. Therefore, SUA in normoglycaemia was an independent risk factor of poor outcome, whereas SUA in DM was only a complementary but not an independent one.

Zhang et al. reported their findings of a similar study in 2012 [12]. The correlation between the SUA level and the poor outcome of stroke in patients with normoglycemia and DM in their study was in line with us; Although the patients in their study were young and mid-age adults (18–45 years old) which was different with us (from 18 to 85 years old), the results were similar. It is a pity that they did not differentiate the prediabetes patients from the ‘real’ normoglycemia patients. Further than their research, we examine the association in prediabetes. Though we did not found a significant association between SUA and poor outcome in prediabetes, concerning the results that the association was much more significant and prominent in normoglycaemia patients than those with abnormal glycometabolism, it was highly implied that glucose metabolism might deeply affect the influence of SUA on post-stroke short-term outcome.

Till now, the effect of SUA on the prognosis of stroke in abnormal glucose metabolism is still debatable. Kramer et al. in their 2010 study reported that hyperuricemia was a significant risk factor for the mortality of cardiovascular disease in patients with pre-diabetes and typeIIdiabetes, but it did not increase the risk of mortality in patients with normoglycemia [7]. Their findings contradicted to our results. The conflicting results might be caused by the different race (Caucasian vs. Chinese) and age (mid-age to elders vs. 18 to 85) of the participants as well as the different sampling time of SUA (pre-event vs. post-event different phases).

Gender difference is attributed to SUA concentration [29, 30], thus effect of SUA on poor functional outcome differs in gender. There is no significant association found in female subgroup in the present study, which is mainly caused by the not large enough sample size (only 290 female stroke patients with normoglycaemia).

The possible mechanisms of the association between post-stroke SUA levels and the outcomes after stroke

There were conflicting results about the association between the post-stroke SUA level and the prognosis of stroke in the literature. Several studies reported that hyperuricemia was a risk factor for the poor outcomes [24] and suggested that the follow adverse effects of uric acid on the cardiovascular system might be the underline reasons: first, Hyperuricemia could cause insulin resistance [31]; second, hyperuricemia could increase the risk of hypertension and further aggravated atherosclerosis [32]; third, hyperuricemia could directly or indirectly impair the self-regulation of the arteriole and increased the risk of stroke [33].

At the meanwhile, results from other studies suggested hyperuricaemia might be a protective factor of stroke [812, 34]. Most of them [8, 1012, 34] were published after the meta-analysis study from Kim, et al. [1]. In another study, administration of uric acid during the thrombolysis procedure in acute ischemic stroke patients had been proven to be neuro-protective [35]. It had also been proven in another study that low SUA was associated with larger infarction area and worse neurological deficit in the stroke patients [36]. The possible mechanisms of this protective effect of SUA included: (1) SUA was one of the most important serum antioxidant factors and an anti-inflammatory factor [3740]; (2) SUA could stabilize endothelia progenitor cells (EPCs) [41]; (3) SUA could decrease the degradation of the extracellular superoxide dismutase-3(SOD3) [42]; (4) In the chronic disease, hyperuricaemia was a reaction of the negative feedback mechanism to counterbalance the increased level of reactive oxygen species (ROS) [43]. It had been proven that Xanthine Oxidase (XO) expression increased after acute ischemic cerebral lesion and the increased XO would further lead to the uric acid level in local brain tissue to increase significantly. The rate of the change in XO and local uric acid level was positively correlated with the severity of the ischemic damage of the brain tissue [44, 45]. In 2010, Brouns, et al. reported the rate of SUA decrease in the first 7 days after stroke was positively correlated with the severity of the stroke as well as the incidence rate of poor post-stroke outcome [46]. Therefore, the concentration of peripheral SUA post stroke is most possibly in a dynamically decreasing pattern but it is still unknown exactly.

This dynamically decreasing pattern of SUA post stroke would attribute to the contradictory results on SUA and poor outcome. Of all the researches, SUA values from the different measurement timing post stroke (some were within 3 days, some were within 14 days, others were within several hours, etc.) could not stand for the SUA level in a concordant post-stroke phase. Since its dynamic changes, the association of SUA and poor outcome was altered concerning a specific population (poor outcome or favorable outcome). For example, as for the patients with poor outcome, when the timing of SUA evaluated was just at the phase of higher SUA level, we might find an adverse effect of SUA on poor outcome, otherwise the effect might find to be protective. Therefore, the diverse investigations on SUA at different phases post stroke might come to paradox results. Further investigation needs to be carried out on figuring out the pattern of SUA concentration post stroke and its association as well the abnormal glucose metabolism on poor prognosis.

Advantages and limitations

ACROSS-CHINA is a nationwide, prospective, multiple-center study. In our study, pre-diabetic patients were excluded by OGTT test result to eliminate their possible interference to the results. There were some limitations in our study. First, only patients with SUA data were included in the study and this might cause selection bias. Second, there were no data of the dynamic change of SUA level. Third, only a few data on medications that might affect the SUA level were collected and no data on non-VKA oral anticoagulants (NOACs). Fourth, lack of data on exercise pre- and post- stroke. Exercise is also a major factor to influence SUA concentration [47].

Conclusions

The associations between post-stroke SUA and poor functional outcome at discharge differ in diverse abnormal glycometabolism populations. In acute stroke patients with normoglycemia, low SUA level (<220 μmol L-1) is an independent risk predictor of poor short-term outcome other than DM or prediabetes. The debated conclusion on the association between SUA and the poor outcome after stroke might be due to the diverse post-stroke time of blood sample for SUA in those different studies. Further research will be conducted on the association between the pattern of SUA change in stroke patients with different time of stroke onset, different glycoemtabolism status, different gender, through recording the dynamic value of SUA post stroke and the poor functional outcome and stratifying the study group by diagnosing glycometabolism status.

Abbreviations

ACROSS-China: 

The abnormal glucose regulation in patients with acute stroke across China study

BMI: 

Body mass index

CI: 

Confidential interval

D1 to D10: 

Decile1 to Decile 10

DM: 

Diabetes mellitus

EPCs: 

Endothelia progenitor cells

FPG: 

Fasting plasma glucose

HOMA2-IR: 

The Homeostasis Model Assessment 2-Insulin Resistance

ICH: 

Intracerebral hemorrhage

IFG: 

Impaired fasting glucose

IGT: 

Impaired glucose tolerance

mRS: 

Modified Rankin Scale

NIHSS: 

The National Institutes of Health Stroke Scale

NOACs: 

Non-VKA oral anticoagulants

OGTT: 

Oral glucose tolerance test

ORs: 

Odds ratios

Q1 to Q4: 

Quartile 1 to quartile 4

ROS: 

Reactive oxygen species

SAH: 

Subarachnoid hemorrhage

SUA: 

Serum uric acid

WHO: 

World Health Organization

XO: 

Xanthine Oxidase

Declarations

Acknowledgements

We thank all the participants in the study.

Funding

The study was supported by Beijing Municipal Science and Technology Commission NO.Z151100004015127 and NO.Z151100003915117. The funding didn’t have a role in the design of the study, collection, analysis, interpretation of data or in writing the manuscript.

Availablility of data and materials

The raw data are available at “Additional file 10”. All the findings are calculated from the raw data by using SPSS. The data is not totally publically available in order to protect participant anonymity.

Authors’ contributions

SLW drafted the manuscript; NZ helped to collect the data; SLW and YSP performed the statistically analysis; CXW participated the design of the study and explanation of the data; YJW participated the design of the study. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interesets.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study was approved by the Ethics Committees at all participating hospitals (See Additional file 11). Written informed consent was obtained from all patients or from the designated family member when the patient was unable to complete it.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Neuropsychiatry and Behavioral Neurology and Clinical Psychology, Beijing Tiantan Hospital, Capital Medical University
(2)
China National Clinical Research Center for Neurological Diseases
(3)
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University
(4)
Center of Stroke, Beijing Institute for Brain Disorders
(5)
Beijing Key Laboratory of Translational Medicine for cerebrovascular Disease

References

  1. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61:885–92.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Weir CJ, Muir SW, Walters MR, et al. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke. 2003;34:1951–6.View ArticlePubMedGoogle Scholar
  3. Karagiannis A, Mikhailidis DP, Tziomalos K, et al. Serum uric acid as an independent predictor of early death after acute stroke. Circ J. 2007;71:1120–7.View ArticlePubMedGoogle Scholar
  4. Newman EJ, Rahman FS, Lees KR, et al. Elevated serum urate concentration independently predicts poor outcome following stroke in patients with diabetes. Diabetes Metab Res Rev. 2006;22:79–82.View ArticlePubMedGoogle Scholar
  5. Chiquete E, Ruiz-Sandoval JL, Murillo-Bonilla LM, et al. Serum uric acid and outcome after acute ischemic stroke: PREMIER study. Cerebrovasc Dis. 2013;35:168–74.View ArticlePubMedGoogle Scholar
  6. Zoppini G, Targher G, Bonora E. The role of serum uric acid in cardiovascular disease in type 2 diabetic and non-diabetic subjects: a narrative review. J Endocrinol Invest. 2011;34:881–6.View ArticlePubMedGoogle Scholar
  7. Holme I, Aastveit AH, Hammar N, et al. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med. 2009;266:558–70.View ArticlePubMedGoogle Scholar
  8. Kramer CK, von Mühlen D, Jassal SK, et al. A prospective study of uric acid by glucose tolerance status and survival: the Rancho Bernardo Study. J Intern Med. 2010;267:561–6.View ArticlePubMedGoogle Scholar
  9. Logallo N, Naess H, Idicula TT, et al. Serumuri acid: neuroprotection in thrombolysis. The Bergen NORSTROKE study. BMC Neurol. 2011;11:114.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Chamorro A, Obach V, Cervera A, et al. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke. 2002;33:1048–52.View ArticlePubMedGoogle Scholar
  11. Zhang B, Gao C, Yang N, et al. Is elevated SUA associated with a worse outcome in young Chinese patients with acute cerebral ischemic stroke? BMC Neurol. 2010;10:82.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Amaro S, Urra X, Gómez-Choco M, et al. Uric acid levels are relevant in patients with stroke treated with thrombolysis. Stroke. 2011;42 Suppl 1:S28–32.View ArticlePubMedGoogle Scholar
  13. Zhang B, Gao C, Hou Q, et al. The potent different risk factors for cerebral infarction in young patients with and without type 2 diabetes: subanalysis of the Young Cerebral Infarction Study (YCIS). Atherosclerosis. 2012;221:215–20.View ArticlePubMedGoogle Scholar
  14. Miedema I, Uyttenboogaart M, Koch M, et al. Lack of association between serum uric acid levels and outcome in acute ischemic stroke. J Neurol Sci. 2012;319:51–5.View ArticleGoogle Scholar
  15. Winnard D, Wright C, Jackson G, et al. Gout, diabetes and cardiovascular disease in the Aotearoa New Zealand adult population: co-prevalence and implications for clinical practice. N Z Med J. 2012;126:53–64.Google Scholar
  16. Wu J, Qiu L, Yan WH, et al. Serum gamma-glutamyltransferase and uric acid levels are associated with impaired fasting glucose in adults from Inner Mongolia, China. BMC Public Health. 2013;13:294.View ArticlePubMed CentralGoogle Scholar
  17. Jia Z, Zhang X, Kang S, Wu Y. Serum uric acid levels and incidence of impaired fasting glucose and type 2 diabetes mellitus: a meta-analysis of cohort studies. Diabetes Res Clin Pract. 2013;101(1):88–96.View ArticleGoogle Scholar
  18. Shani M, Vinker S, Dinour D, Leiba M, Twig G, Holtzman EJ, Leiba A. High Normal Uric Acid Levels Are Associated with an Increased Risk of Diabetes in Lean, Normoglycemic Healthy Women. J Clin Endocrinol Metab. 2016;101(10):3772–8.View ArticleGoogle Scholar
  19. Jia Q, Zhao X, Wang C, et al. Diabetes and poor outcomes within 6 months after acute ischemic stroke:the China National Stroke Registry. Stroke. 2011;42:2758–62.Google Scholar
  20. Jia Q, Zheng H, Zhao X, et al. Abnormal glucose regulation in patients with acute stroke across China: prevalence and baseline patient characteristics. Stroke. 2012;43:650–7.View ArticleGoogle Scholar
  21. Task WHO. Force on Stroke and other Cerebrovascular Disorders. Stroke-1989: Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke. 1989;20:1407–21.View ArticleGoogle Scholar
  22. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006;29:43–8.Google Scholar
  23. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program (Letter). Diabetes Care. 1998;21:2191–2.View ArticleGoogle Scholar
  24. Kamouchi M, Matsuki T, Hata J, et al. Prestroke glycemic control is associated with the functional outcome in acute ischemic stroke: the Fukuoka Stroke Registry. Stroke. 2011;42:2788–94.View ArticleGoogle Scholar
  25. Theofanidis D. Validation of international stroke scales for use by nurses in Greek settings. Top Stroke Rehabil. 2016:1–8. [Epub ahead of print] PubMed PMID: 27680397.Google Scholar
  26. Yong M, Kaste M. Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial. Stroke. 2008;39:2749–55.View ArticleGoogle Scholar
  27. Weimar C, Mieck T, Buchthal J, Ehrenfeld CE, Schmid E, Diener HC. Neurologic worsening during the acute phase of ischemic stroke. Arch Neurol. 2005;62:393–7.View ArticleGoogle Scholar
  28. Menon RK, Mikhailidis DP, Bell JL, Kernoff PB, Dandona P. Warfarin administration increases uric acid concentrations in plasma. Clin Chem. 1986;32(8):1557–9.Google Scholar
  29. Chou P, Lin KC, Lin HY, Tsai ST. Gender differences in the relationships of serum uric acid with fasting serum insulin and plasma glucose in patients without diabetes. J Rheumatol. 2001;28(3):571–6.Google Scholar
  30. Antón FM, García Puig J, Ramos T, González P, Ordás J. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. Metabolism. 1986;35(4):343–8.View ArticleGoogle Scholar
  31. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care. 2002;25:1790–4.View ArticleGoogle Scholar
  32. Rich MW. Uric acid: is it a risk factor for cardiovascular disease? Am J Cardiol. 2000;85:1018–21.View ArticleGoogle Scholar
  33. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183–90.View ArticleGoogle Scholar
  34. Wu H, Jia Q, Liu G, et al. Decreased Uric Acid Levels Correlate with Poor Outcomes in Acute Ischemic Stroke Patients, but Not in Cerebral Hemorrhage Patients. J Stroke Cerebrovasc Dis. 2014;23(3):469–75.View ArticleGoogle Scholar
  35. Amaro S, Planas AM, Chamorro A. Uric acid administration in patients with acute stroke: a novel approach to neuroprotection. Expert Rev Neurother. 2008;8:259–70.View ArticleGoogle Scholar
  36. Leinonen JS, Ahonen JP, Lönnrot K, et al. Low plasma antioxidant activity is associated with high lesion volume and neurological impairment in stroke. Stroke. 2000;31:33–9.View ArticleGoogle Scholar
  37. Nieto FJ, Iribarren C, Gross MD, et al. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000;148:131–9.View ArticleGoogle Scholar
  38. Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. ProcNatlAcadSci U S A. 1981;78:6858–62.View ArticleGoogle Scholar
  39. Davies KJ, Sevanian A, Muakkassah-Kelly SF, et al. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J. 1986;235:747–54.View ArticlePubMed CentralGoogle Scholar
  40. Zare F, Magnusson M, Bergström T, et al. Uric acid, a nucleic acid degradation product, down-regulates dsRNA-triggered arthritis. J Leukoc Biol. 2006;79:482–8.View ArticleGoogle Scholar
  41. Patschan D, Patschan S, Gobe GG, et al. Uric acid heralds ischemic tissue injury to mobilize endothelial progenitor cells. J Am SocNephrol. 2007;18:1516–24.Google Scholar
  42. Hink HU, Santanam N, Dikalov S, et al. Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. ArteriosclerThrombVasc Biol. 2002;22:1402–8.View ArticleGoogle Scholar
  43. Doehner W, Landmesser U. Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options. SeminNephrol. 2011;31:433–40.Google Scholar
  44. George J, Struthers AD. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag. 2009;5:265–72.View ArticlePubMedPubMed CentralGoogle Scholar
  45. Higgins P, Ferguson LD, Walters MR. Xanthine oxidase inhibition for the treatment of stroke disease: a novel therapeutic approach. Expert Rev CardiovascTher. 2011;9:399–401.View ArticleGoogle Scholar
  46. Brouns R, Wauters A, Van De Vijver G, et al. Decrease in uric acid in acute ischemic stroke correlates with stroke severity, evolution and outcome. ClinChem Lab Med. 2010;48:383–90.Google Scholar
  47. Green HJ, Fraser IG. Differential effects of exercise intensity on serum uric acid concentration. Med Sci Sports Exerc. 1988;20(1):55–9.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement